Core Viewpoint - The innovative drug sector experienced a significant rally, with notable stock price increases among various companies [1] Group 1: Company Performance - Weikang Pharmaceutical saw its stock price rise by over 18% [1] - Qianfang Bio and Shanghai Yizhong both increased by more than 10% [1] - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical also experienced upward movement in their stock prices [1]

Core Insights - Jiangsu Lianhuan Pharmaceutical has submitted a listing application for the generic drug "Edaravone and Right-Butanol Injection Solution," which has been accepted by the National Medical Products Administration (NMPA) [1][2] - This submission follows a failed application by Shanghai Kaibao Xinyi Pharmaceutical on November 14, 2025, indicating a competitive landscape for this drug [1][5] - The original drug, developed by Shensheng Pharmaceutical, was approved in July 2020 and has shown significant market performance, with sales reaching 1.4 billion yuan in 2021 and over 2.5 billion yuan in 2022 [4] Market Dynamics - The market for Edaravone and Right-Butanol Injection Solution is expected to grow due to the increasing incidence of stroke and an aging population [8] - The original product's inclusion in the national medical insurance directory has improved patient accessibility, laying a foundation for the market expansion of generics [8] - Currently, 12 domestic pharmaceutical companies, including Jiangsu Lianhuan, are competing for the first generic version of this drug, intensifying the competition [5][11] Competitive Landscape - If Jiangsu Lianhuan's application is approved, it may become the first generic producer, potentially reshaping the market dynamics and enhancing its strategic positioning in the generic drug sector [11][12] - The ongoing competition among 12 companies suggests that the market for this 21 billion yuan drug is on the verge of significant transformation [12]

1月7日，联环药业盘中下跌2.00%，截至13:42，报19.10元/股，成交1.81亿元，换手率3.27%，总市值 54.52亿元。 资金流向方面，主力资金净流出1655.95万元，特大单买入0.00元，占比0.00%，卖出646.07万元，占比 3.58%；大单买入2329.57万元，占比12.90%，卖出3339.44万元，占比18.49%。 联环药业今年以来股价涨4.31%，近5个交易日涨2.52%，近20日涨3.02%，近60日跌0.62%。 资料显示，江苏联环药业股份有限公司位于江苏省扬州生物健康产业园健康一路9号，成立日期2000年2 月22日，上市日期2003年3月19日，公司主营业务涉及化学药品的研发、生产及销售。主营业务收入构 成为：药品70.01%，医疗器械23.89%，其他6.11%。 联环药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗流感、创新药、生物 医药、小盘、禽流感药物等。 截至9月30日，联环药业股东户数4.66万，较上期增加54.72%；人均流通股6130股，较上期减少 35.37%。2025年1月-9月，联环药业实现营业收入20.82亿元，同比增长 ...

Group 1 - The core announcement is that Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the drug named Meiasartan Potassium Tablets [2] Group 2 - The approval of the drug registration certificate indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio and market presence [2] - The drug Meiasartan Potassium Tablets may contribute to the company's revenue growth and competitive positioning in the pharmaceutical industry [2]

Core Viewpoint - The company has received a drug registration certificate for Benazepril Potassium Tablets, which will enhance its product line and market competitiveness [1] Group 1: Company Developments - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has been approved by the National Medical Products Administration for the registration of Benazepril Potassium Tablets [1] - The approved dosage forms are 40mg and 80mg, which are intended for the treatment of adult primary hypertension [1] - The acquisition of the drug registration certificate is expected to enrich the product line of the company and its subsidiaries [1] Group 2: Market Impact - The approval is anticipated to improve the market competitiveness of the company's products [1] - The company does not expect a significant impact on its recent operating performance from this approval [1]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513) announced the approval of its subsidiary Changle Pharmaceutical's drug, Benazepril Potassium Tablets, by the National Medical Products Administration, which can be used for the treatment of primary hypertension in adults [1] Group 2 - The drug Benazepril Potassium Tablets has received a drug registration certificate, indicating its compliance with regulatory standards [1] - This approval may enhance the company's product portfolio and market presence in the hypertension treatment segment [1] - The approval reflects the ongoing efforts of the company to expand its pharmaceutical offerings and address health issues related to hypertension [1]

证券代码：600513 证券简称：联环药业 公告编号：2025-102 江苏联环药业股份有限公司 关于控股子公司获得《药品注册证书》的公告 沙坦钾片销售额达 5,873.19 万元（数据来源于摩熵·医药数据库）。 2024年8月，常乐制药首次递交美阿沙坦钾片（40mg/80mg）注册申请并获受 理，近日常乐制药收到国家药监局核准签发的美阿沙坦钾片（40mg/80mg）《药 品注册证书》。常乐制药美阿沙坦钾片（40mg/80mg）按照化学药品4类进行申报， 根据国家相关政策，本次获得《药品注册证书》视同通过仿制药质量和疗效一致 性评价。 截至本公告披露日，常乐制药美阿沙坦钾片（40mg/80mg）研发投入约为人 民币1,099.00万元（未经审计）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）控股子公司新乡市常乐 制药有限责任公司（以下简称"常乐制药"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关情况公 告如下： | 药品名称 | ...

Core Viewpoint - The company announced that its subsidiary, Changle Pharmaceutical, received approval from the National Medical Products Administration for the registration of Mezasartan Potassium Tablets (40mg/80mg), which are used to treat primary hypertension in adults [1] Group 1 - The research and development investment for Mezasartan Potassium Tablets amounted to approximately RMB 10.99 million [1] - As of the announcement date, Changle Pharmaceutical has obtained 10 production licenses for the product [1] - The approval of the drug registration certificate is not expected to have a significant impact on the company's recent operating performance [1]

Core Viewpoint - The company has received a drug registration certificate for its product, Amlodipine Besylate Tablets, which is expected to enhance its product line and market competitiveness [1]. Group 1: Product Development - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has been granted a drug registration certificate by the National Medical Products Administration for Amlodipine Besylate Tablets [1]. - The product is indicated for the treatment of primary hypertension in adults, with projected sales of approximately 58.73 million yuan in 2024 [1]. - The registration application for Amlodipine Besylate Tablets (40mg/80mg) was first submitted in August 2024 and has now been approved, signifying compliance with the consistency evaluation of generic drug quality and efficacy [1]. Group 2: Financial Investment - The research and development investment for Amlodipine Besylate Tablets has reached approximately 10.99 million yuan (unaudited) as of the announcement date [1]. - The company has obtained 10 production licenses for the product as of the announcement date [1]. Group 3: Market Impact - The acquisition of the drug registration certificate is expected to enrich the company's product line and enhance the competitiveness of its products in the market [1]. - The impact of this registration on the company's recent operating performance is not anticipated to be significant [1].

Core Viewpoint - The announcement by Lianhuan Pharmaceutical regarding the approval of its subsidiary Changle Pharmaceutical's drug, Amlodipine Besylate Tablets, indicates progress in the company's product pipeline, although it is not expected to significantly impact recent financial performance [2] Group 1: Company Developments - Lianhuan Pharmaceutical's subsidiary, Changle Pharmaceutical, received the drug registration certificate for Amlodipine Besylate Tablets (40mg/80mg) from the National Medical Products Administration [2] - The research and development investment for Amlodipine Besylate Tablets amounted to approximately RMB 10.99 million [2] - As of the announcement date, Changle Pharmaceutical has obtained 10 production licenses for its products [2] Group 2: Market Impact - The approval of Amlodipine Besylate Tablets is intended for the treatment of primary hypertension in adults [2] - The company anticipates that this approval will not have a significant impact on its recent operating performance [2]